Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLEVOFLOXACIN (levofloxacin) by Rubicon Biotechnology is 12. Approved for plague, including pneumonic, septicemic plague and 43 more indications. First approved in 2010.
Drug data last refreshed 20h ago
12.1 Mechanism of Action Levofloxacin is a member of the fluoroquinolone class of anti-infective drugs. (See ) 12.2 Pharmacokinetics Levofloxacin concentration in plasma was measured in 15 healthy adult volunteers at various time points during a 15-day course of treatment with levofloxacin…
Worked on LEVOFLOXACIN at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Fluoroquinolone Antibacterial
A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
Levofloxacin Ocular Implant for Ocular Surgery
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo